Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Samsung Invests $10M in CS2 Diagnostics | Contract Pharma

What are you searching for?

Sign in
Breaking News

Samsung Invests $10M in CS2 Diagnostics

Bolsters C2N’s ability to further scale its clinical laboratory services and advanced diagnostic solutions in the field of brain health.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

C2N Diagnostics, LLC, a specialty diagnostics company, has received a $10 million investment from Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment Corporation—bolstering its ability to further scale its clinical laboratory services and advanced diagnostic solutions in the field of brain health.

Dr. Joel Braunstein, CEO of C2N, said, “Samsung is an international leader and widely recognized for the seriousness and thorough reviews it undertakes in its strategic decisions. We greatly appreciate the confidence Samsung brings to this partnership as we believe it affirms the value and quality of our advanced diagnostic solutions. Samsung’s important investment will allow C2N to further strengthen our capabilities, expand our commercial scale, and innovate next generation diagnostic tests that can improve patients’ lives.”

Jaywoo Kim, Executive Vice President of Samsung C&T Corporation, said, “We are confident that C2N Diagnostics will further grow its leading position in the industry by serving global biopharma customers as well as medical service providers with its well-established blood biomarker testing portfolio.”

Through this strategic investment, C2N aims to continue accelerating organizational capabilities to ensure patients globally have access to C2N’s blood biomarker testing technologies for Alzheimer’s disease and related dementias.

The Journal of the American Medical Association (JAMA) recently published a clinical study examining the ability of C2N’s PrecivityAD2 blood test algorithm to improve the diagnostic accuracy of Alzheimer’s disease in primary care settings. The study found similar robustness of test performance in patients who saw memory care specialists. The PrecivityAD2 test result delivered a highly statistically significant accuracy of over 90% at a pre-defined, single binary cutoff compared to cerebrospinal fluid (CSF) analysis or amyloid PET analysis.

C2N is now expanding the biomarker pipeline by developing advanced assays targeting tau pathology, Parkinson’s disease research, and developing technologies to decentralize mass spectrometry testing.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters